Gracell Biotechnologies I... (GRCL)
10.25
0.01 (0.05%)
At close: Feb 21, 2024, 9:00 PM
0.05% (1D)
| Bid | n/a |
| Market Cap | 989.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -496.98M |
| EPS (ttm) | -0.97 |
| PE Ratio (ttm) | -10.56701030927835 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 6,373,187 |
| Avg. Volume (20D) | 1,464,475 |
| Open | 10.26 |
| Previous Close | 10.24 |
| Day's Range | 10.17 - 10.28 |
| 52-Week Range | 1.40 - 10.44 |
| Beta | -0.34 |
About GRCL
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate,...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 8, 2021
Employees 314
Stock Exchange NASDAQ
Ticker Symbol GRCL
Website https://www.gracellbio.com